Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080763 | 0.90 | CNR2 (0.44) | CNR2SLC2A1SIGMAR1KCNH2MELK | |
| SCHEMBL5747690 | 0.88 | KCNH2 (0.50) | CNR2SLC2A1KCNH2 | |
| SCHEMBL6079976 | 0.85 | SLC2A1 (0.38) | CNR2UBE2MDCUN1D1CNR1HTR7 | |
| SCHEMBL6079967 | 0.85 | SLC2A1 (0.38) | CNR2UBE2MDCUN1D1CNR1HTR7 | |
| SCHEMBL5744836 | 0.82 | SSTR2 (0.48) | CNR1SLC2A1KCNH2 | |
| SCHEMBL3984347 | 0.80 | KCNH2 (0.39) | UBE2MDCUN1D1HTR7SLC2A1SIGMAR1 | |
| SCHEMBL6079889 | 0.80 | KCNH2 (0.47) | CNR2SLC2A1SIGMAR1KCNH2 | |
| SCHEMBL5746904 | 0.78 | KCNH2 (0.62) | KCNH2 | |
| SCHEMBL5744942 | 0.77 | SLC2A1 (0.67) | CNR2HTR7SLC2A1SIGMAR1MCHR1 | |
| SCHEMBL6080508 | 0.76 | SLC2A1 (0.40) | CNR2SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | CNR2 4489/4885UBE2M 727/4885DCUN1D1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.